Skip to main content

Langerhans Cell Histiocytosis

4
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
3 programs
3
CytarabinePhase 21 trial
methotrexatePhase 21 trial
thalidomide combined with dexamethasone and cyclophosphamidePhase 21 trial
Active Trials
NCT04121819Unknown40Est. Dec 2021
NCT02389400Completed43Est. Sep 2017
NCT04120519Unknown20Est. Dec 2021
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK2110183Phase 2
Fosun Pharma
Fosun PharmaAustralia - Sydney
1 program
FCN-159PHASE_21 trial
Active Trials
NCT05997602Recruiting56Est. May 2027
GSK
GSKLONDON, United Kingdom
1 program
GSK2110183PHASE_21 trial
Active Trials
NCT01395004Completed17Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Fosun PharmaFCN-159
UNION therapeuticsthalidomide combined with dexamethasone and cyclophosphamide
UNION therapeuticsCytarabine
UNION therapeuticsmethotrexate
GSKGSK2110183

Clinical Trials (5)

Total enrollment: 176 patients across 5 trials

NCT05997602Fosun PharmaFCN-159

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Start: Sep 2023Est. completion: May 202756 patients
Phase 2Recruiting
NCT04120519UNION therapeuticsthalidomide combined with dexamethasone and cyclophosphamide

Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis

Start: Oct 2019Est. completion: Dec 202120 patients
Phase 2Unknown
NCT04121819UNION therapeuticsCytarabine

AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis

Start: Oct 2019Est. completion: Dec 202140 patients
Phase 2Unknown
NCT02389400UNION therapeuticsmethotrexate

Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis

Start: Jan 2014Est. completion: Sep 201743 patients
Phase 2Completed
NCT01395004GSKGSK2110183

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

Start: Nov 2011Est. completion: Nov 201317 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 176 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.